Minerva Neurosciences Achieves Objectives in Phase 2b Clinical Trial of Seltorexant in Insomnia
Minerva Neurosciences Inc reports results of a clinical trial (ISM2005) of seltorexant (MIN-202) in patients with insomnia disorder that demonstrated highly statistically significant (p ?0.001) and clinically meaningful...
Read More